Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|April 3, 1999
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerK J O'Byrne, N Dobbs, D J Propper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tractJ P Braybrooke, K J O'Byrne, M P Saunders, et al.
British Journal of Cancer|June 16, 2005
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerN C Levitt, D J Propper, S Madhusudan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effectsD J Propper, M P Saunders, A J Salisbury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000D J Propper, J de Bono, A Saleem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumoursD J Propper, J P Braybrooke, D J Taylor, et al.
British Journal of Cancer|June 6, 2000
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancerD J Propper, N C Levitt, K O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinomaK J O'Byrne, P A Philip, D J Propper, et al.
British Journal of Cancer|July 20, 2000
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alphaJ P Braybrooke, D J Propper, K J O'Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Pageof 4